D-Index & Metrics Best Publications

Oliver Distler

University of Zurich
Switzerland

Medicine

Switzerland

2023

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 102 Citations 38,977 763 World Ranking 4506 National Ranking 56

Research.com Recognitions

Awards & Achievements

2023 - Research.com Medicine in Switzerland Leader Award

Overview

What is he best known for?

The fields of study Oliver Distler is best known for:

GERD
Autoimmune disease
Omeprazole

As part of his studies on Internal medicine, Oliver Distler frequently links adjacent subjects like Bedtime. The study of Bedtime is intertwined with the study of Internal medicine in a number of ways. In his papers, Oliver Distler integrates diverse fields, such as Randomized controlled trial and Placebo. He incorporates Placebo and Alternative medicine in his research. Oliver Distler undertakes multidisciplinary studies into Alternative medicine and Randomized controlled trial in his work. His Reflux study frequently draws connections between related disciplines such as Disease. In most of his Disease studies, his work intersects topics such as Reflux. Oliver Distler performs multidisciplinary studies into Ranitidine and Omeprazole in his work. Oliver Distler combines Omeprazole and Gastric acid in his studies.

His most cited work include:

Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study (73 citations)
Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis - a randomized controlled, cross-over trial (28 citations)

What are the main themes of his work throughout his whole career to date

His Receptor research is covered under the topics of Agonist and Serotonin. As part of his studies on Agonist, he frequently links adjacent subjects like Receptor. He regularly ties together related areas like Logistic regression in his Internal medicine studies. His Pathology study frequently links to other fields, such as Clinical trial. His Clinical trial study frequently draws connections between adjacent fields such as Pathology. Inoculation is closely attributed to Scleroderma (fungus) in his study. In most of his Scleroderma (fungus) studies, his work intersects topics such as Immunology. His Immunology study frequently links to related topics such as Inoculation. His multidisciplinary approach integrates Dermatology and Rheumatology in his work.

Oliver Distler most often published in these fields:

Internal medicine (90.00%)
Pathology (50.00%)
Inoculation (40.00%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative

Frank Van Den Hoogen;Dinesh Khanna;Jaap Fransen;Sindhu R. Johnson.
Arthritis & Rheumatism (2013)

3803 Citations

Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

Anthony J. Tyndall;Bettina Bannert;Madelon Vonk;Paolo Airò.
Annals of the Rheumatic Diseases (2010)

1162 Citations

Anti–Tumor Necrosis Factor-α Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis

David Hürlimann;Adrian Forster;Georg Noll;Frank Enseleit.
Circulation (2002)

911 Citations

Update of EULAR recommendations for the treatment of systemic sclerosis

Otylia Kowal-Bielecka;Jaap Fransen;Jerome Avouac;Mike Becker;Mike Becker.
Annals of the Rheumatic Diseases (2015)

796 Citations

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

Oliver Distler;Martina Gahlemann;Toby M Maher.
The New England Journal of Medicine (2019)

788 Citations

Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis

Alfiya Akhmetshina;Katrin Palumbo;Clara Dees;Christina Bergmann.
Nature Communications (2012)

725 Citations

Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study

J Gerry Coghlan;Christopher P Denton;Ekkehard Grünig;Diana Bonderman.
Annals of the Rheumatic Diseases (2014)

716 Citations

Synovial fibroblasts: key players in rheumatoid arthritis

L. C. Huber;O. Distler;I. Tarner.
Rheumatology (2006)

654 Citations

MicroRNA-29, a key regulator of collagen expression in systemic sclerosis.

Britta Maurer;Joanna Stanczyk;Astrid Jüngel;Alfiya Akhmetshina.
Arthritis & Rheumatism (2010)

577 Citations

Angiogenic and angiostatic factors in the molecular control of angiogenesis.

J H W Distler;A Hirth;M Kurowska-Stolarska.
The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (2003)

523 Citations

If you think any of the details on this page are incorrect, let us know.